For Patients with HER2-Negative Breast Cancer, Neoadjuvant Chemotherapy Plus Bevacizumab Not Effective
the Cancer Therapy Advisor take:
According to a new study published in the journal Annals of Oncology, researchers in Germany have found that neoadjuvant treatment with anthracycline-taxane-based chemotherapy or treatment with everolimus plus paclitaxel in patients with triple negative breast cancer is not effective.
Early results of the GeparQuinto study demonstrated that neoadjuvant anthracycline-taxed based chemotherapy with bevacizumab increased pathological complete response rates in patients with triple negative breast cancer. The study also showed that patients who were non-responders to that regimen who then received everolimus plus paclitaxel had no difference in pathological complete response compared with those that received paclitaxel alone.
The long-term results show a 3-year disease-free survival rate of 80.8% and a 3-year overall survival rate of 89.7% in both groups of patients with breast cancer that received epirubin, cyclophosphamide, and docetaxel with or without bevacizumab. In addition, there was no difference in disease-free survival or overall survival rates between early non-responders that received paclitaxel with or without everolimus.
Although early results demonstrated increased pathological complete response rates in patients with breast cancer, particularly triple negative breast cancer, these long-term results to do not support the use of adding bevacizumab or everolimus.
Neoadjuvant treatment with anthracycline-taxane-based chemotherapy in breast cancer not effective.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC
- Pembrolizumab Alone or With Chemotherapy Prolongs OS in Recurrent/Metastatic HNSCC
- Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma
- Assays May Help Researchers Discover Factors Underlying Immunotherapy Response
- Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer